U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07483476) titled 'Study of Cell-free DNA in Children and Adolescents With Acute Lymphoblastic Leukemia' on March 16.
Brief Summary: Minimal residual disease (MRD) monitoring is a key prognostic factor in pediatric acute lymphoblastic leukemia (ALL). Currently, MRD assessment relies mainly on cellular DNA obtained from bone marrow aspirates. Although highly informative, this approach has limitations, including the need for invasive procedures and the fact that it reflects only the bone marrow compartment.
Tumor cells release fragments of genomic DNA into the bloodstream, known as circulating cell-free DNA (cfDNA). In solid tumors, cfDNA analysis has...